# **Screening Libraries**

# **BCI-215**

Cat. No.: HY-121087 CAS No.: 1245792-67-9 Molecular Formula:  $C_{22}H_{22}BrNO$ Molecular Weight: 396.32

Target: Phosphatase

Pathway: Metabolic Enzyme/Protease

Storage: Powder -20°C 3 years 4°C 2 years

In solvent -80°C 2 years

> -20°C 1 year

**Product** Data Sheet

# **SOLVENT & SOLUBILITY**

In Vitro

DMSO: 33.33 mg/mL (84.10 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	2.5232 mL	12.6161 mL	25.2321 mL
	5 mM	0.5046 mL	2.5232 mL	5.0464 mL
	10 mM	0.2523 mL	1.2616 mL	2.5232 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 0.83 mg/mL (2.09 mM); Clear solution
- 2. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 0.83 mg/mL (2.09 mM); Clear solution

# **BIOLOGICAL ACTIVITY**

Description	BCI-215 is a potent and tumor cell-selective dual specificity MAPK phosphatase (DUSP-MKP) inhibitor. BCI-215 has cytotoxicity for tumor cells but not normal cells <sup>[1][2]</sup> .
IC <sub>50</sub> & Target	DUSP-MKP <sup>[1]</sup>
In Vitro	BCI-215 concentration-dependently increases pERK levels in DUSP-overexpressing cells with IC $_{50}$ value in the micromolar range $^{[1]}$ .  BCI-215 (1-20 $\mu$ M; 6 hours) retains fibroblast growth factor hyperactivating and cellular DUSP6/MKP-3 and DUSP1/MKP-1 inhibitory activity but is nontoxic to zebrafish embryos and an endothelial cell line $^{[1]}$ .  BCI-215 inhibits survival and motility of MDA-MB-231 human breast cancer cells but does not affect viability of cultured

hepatocytes<sup>[2]</sup>.

BCI-215 is completely devoid of hepatocyte toxicity up to 100  $\mu\text{M}^{[2]}.$ 

BCI-215 does not generate ROS in hepatocytes or in developing Zebrafish larvae. BCI-215 (22  $\mu$ M) has antimigratory and proapoptotic activities in breast cancer cells that correlate with induction of ERK phosphorylation<sup>[2]</sup>.

BCI-215 (20  $\mu$ M; 1 hour) induces mitogenic and stress signaling in cancer cells without generating ROS [2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Apoptosis Analysis [2]

Cell Line:	MDA-MB-231 cells	
Concentration:	22 μΜ	
Incubation Time:		
Result:	Caused apoptotic cell death at concentrations that induce ERK phosphorylation.	
Western Blot Analysis <sup>[2]</sup>		
Cell Line:	MDA-MB-231 cells	
Concentration:	20 μΜ	
Incubation Time:	1 hour	
Result:	Induced a stress response that is not dependent on oxidation.	

# **CUSTOMER VALIDATION**

• Molecules. 2022 Aug 25;27(17):5449.

See more customer validations on www.MedChemExpress.com

## **REFERENCES**

[1]. Korotchenko VN, et al. In vivo structure-activity relationship studies support allosteric targeting of a dual specificity phosphatase. Chembiochem. 2014 Jul 7;15(10):1436-45.

[2]. Kaltenmeier CT, et al. A Tumor Cell-Selective Inhibitor of Mitogen-Activated Protein Kinase Phosphatases Sensitizes Breast Cancer Cells to Lymphokine-Activated Killer Cell Activity. J Pharmacol Exp Ther. 2017 Apr;361(1):39-50.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

 $\hbox{E-mail: } tech@MedChemExpress.com$ 

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA